Substituted Quinoxaline Bridged-Piperidine Polymorphs for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of substituted-quinoxaline-type bridged piperidine compounds lack stable crystalline forms that affect solubility, stability, and efficacy, necessitating the identification and control of solid forms to ensure drug safety and effectiveness.
Innovation Solution
Development of novel crystalline forms of substituted-quinoxaline-type bridged piperidine compounds, including Forms A, B, C, and E, characterized by specific XRPD patterns and thermal properties, which exhibit high purity and stability, suitable for pharmaceutical compositions and dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmaceutical formulations are used, then the compound can be administered for treatment, but the solubility, stability, and efficacy are insufficient due to lack of stable crystalline forms
Solution Approach 1:
The patent applies parameter changes by identifying and characterizing multiple polymorphic forms (Forms A, B, C, D, E) of the compound, each with distinct crystalline structures and properties. By changing the physical state and crystalline arrangement parameters, the formulation achieves improved solubility, stability, and efficacy while establishing controlled solid forms for reliable manufacturing
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining the compound in specific crystalline forms with pharmaceutically acceptable excipients and carriers. This composite approach allows optimization of solubility and stability profiles while maintaining manufacturability through controlled solid form selection
2Productivity
If new crystalline forms are developed, then solubility and efficacy are improved, but the complexity of identifying and characterizing solid forms increases
Solution Approach 1:
The patent applies preliminary action by systematically investigating and characterizing multiple polymorphic forms before selecting the optimal form for pharmaceutical use. The detailed XRPD patterns, thermal analysis, and solubility studies of Forms A, B, C, D, and E are performed in advance to establish which form provides the best efficacy while simplifying subsequent manufacturing and quality control
Solution Approach 2:
The patent replaces complex mechanical characterization methods with advanced analytical techniques such as X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). These analytical substitutions enable precise identification and differentiation of crystalline forms without requiring complex mechanical testing, thereby improving efficacy assessment while managing characterization complexity
3Reliability
If crystalline forms are controlled for safety and efficacy, then drug product quality is improved, but the manufacturing process becomes more complex
Solution Approach 1:
The patent applies local quality by selecting specific crystalline forms (Forms A, B, C, D, or E) with locally optimized properties for different pharmaceutical applications. Each polymorphic form has distinct solubility, stability, and bioavailability characteristics that can be tailored to specific drug product requirements, thereby improving quality while managing manufacturing complexity through form-specific process optimization
Solution Approach 2:
The patent establishes universal manufacturing approaches that can produce multiple crystalline forms using similar pharmaceutical excipients and processing techniques. The identified polymorphic forms can be manufactured using conventional pharmaceutical equipment and processes, providing multi-functionality that improves drug product quality without excessively complicating the manufacturing process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crystalline forms enhance the solubility, stability, and efficacy of pharmaceutical products, providing effective treatment and management of pain and sleep disorders, including insomnia and alcohol-induced sleep disorders, with improved bioavailability and reduced degradation.
Implementation Method 1
characterized by powder X-ray diffraction ('PXRD' or 'XRPD') crystallography
Implementation Method 2
a non-solvated crystalline form of a compound of Formula (I), referred to herein as Form A, has a XRPD pattern
Implementation Method 3
characterized by powder X-ray diffraction ('PXRD' or 'XRPD') crystallography
Data Source
AI summary
Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described herein are particularly useful for treatment, prevention, and management of several sleep disorders.